| Literature DB >> 25942495 |
Coralie Viollet1, David A Davis2, Martin Reczko3, Joseph M Ziegelbauer2, Francesco Pezzella4, Jiannis Ragoussis5, Robert Yarchoan2.
Abstract
Kaposi's sarcoma associated herpesvirus (KSHV) causes several tumors, including primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS). Cellular and viral microRNAs (miRNAs) have been shown to play important roles in regulating gene expression. A better knowledge of the miRNA-mediated pathways affected by KSHV infection is therefore important for understanding viral infection and tumor pathogenesis. In this study, we used deep sequencing to analyze miRNA and cellular mRNA expression in a cell line with latent KSHV infection (SLKK) as compared to the uninfected SLK line. This approach revealed 153 differentially expressed human miRNAs, eight of which were independently confirmed by qRT-PCR. KSHV infection led to the dysregulation of ~15% of the human miRNA pool and most of these cellular miRNAs were down-regulated, including nearly all members of the 14q32 miRNA cluster, a genomic locus linked to cancer and that is deleted in a number of PEL cell lines. Furthermore, we identified 48 miRNAs that were associated with a total of 1,117 predicted or experimentally validated target mRNAs; of these mRNAs, a majority (73%) were inversely correlated to expression changes of their respective miRNAs, suggesting miRNA-mediated silencing mechanisms were involved in a number of these alterations. Several dysregulated miRNA-mRNA pairs may facilitate KSHV infection or tumor formation, such as up-regulated miR-708-5p, associated with a decrease in pro-apoptotic caspase-2 and leukemia inhibitory factor LIF, or down-regulated miR-409-5p, associated with an increase in the p53-inhibitor MDM2. Transfection of miRNA mimics provided further evidence that changes in miRNAs are driving some observed mRNA changes. Using filtered datasets, we also identified several canonical pathways that were significantly enriched in differentially expressed miRNA-mRNA pairs, such as the epithelial-to-mesenchymal transition and the interleukin-8 signaling pathways. Overall, our data provide a more detailed understanding of KSHV latency and guide further studies of the biological significance of these changes.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25942495 PMCID: PMC4420468 DOI: 10.1371/journal.pone.0126439
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Relative abundance of human and KSHV-encoded miRNAs in KSHV-positive SLKK cells.
The expression levels of KSHV miRNAs are shown as the percentage of the total of viral miRNA reads. Data are the mean of sequenced samples from three independent experiments, each with two technical replicates with opposite sequencing directions. Percentages have been rounded to the closest digit. For a detailed presentation, see S2 and S3 Tables.
Fig 2Expression of miRNAs and mRNAs in the analyzed libraries.
A. Volcano plot of differentially expressed human mature miRNAs in KSHV-infected versus uninfected cells. Vertical red lines indicate the threshold for a relative expression fold change (FC) of 2 or -2 fold compared to uninfected controls. The horizontal red line represents the threshold of a 0.05 P-value. Thus, the blue points lying in the top right and top left sectors are significantly up-regulated and down-regulated, respectively, in KSHV-positive versus KSHV-negative cells (P <0.05, FC ≥2 or ≤-2). Selected miRNAs that have been validated by qRT-PCR are labeled. B. Volcano plot of differentially expressed mRNAs in KSHV-infected versus uninfected cells. The plot is depicted as in Fig 2A, with vertical and horizontal red lines similarly representing the thresholds of a fold-change of 2 or -2 fold, and of a false-discovery rate (FDR) of 0.05 respectively. C. Top 15 repressed and induced miRNAs in KSHV-positive vs. uninfected SLK cells with P <0.05 and medium to high miRNA expression (threshold of a mean miR count of 10 or more across all replicates).
Fig 3Analysis of miRNA expression in latent and de novo KSHV-infected cells.
A. Data represent the average log2-transformed fold change of expression between latently infected SLKK cells and uninfected SLK cells, measured either by small RNA sequencing (black bars) or Taqman assay (grey bars). All the changes are significant (P≤0.05) except that of miR-210 as detected by miRNA-Seq. B. Effects of de novo KSHV infection on miRNAs seen down-regulated in the SLK/SLKK model. SLK cells were exposed to KSHV and after 5 days, changes in specific miRNAs were assessed by Taqman assay. The dotted line indicates the normalized level of these miRNAs in uninfected SLK cells. P-values were calculated using Student t-test. ** indicates P <0.01. ns: not significant. Expression levels of mature miRNAs were evaluated using the comparative CT method (2-deltaCT). Transcript levels of RNU43 were used for sample normalization. Bars depict the mean of 3 independent experiments; error bars reflect the standard deviation.
Fig 4Differential expression of miRNAs and their known or predicted mRNA targets.
A. miRNA expression in latently infected SLKK cells compared to uninfected SLK cells and the mRNA expression of their corresponding targets (Taqman and qRT-PCR assays). miRNAs and mRNAs are shown in light and dark grey, respectively. miR-409-3p targets fibrinogen beta (FGB) and radixin (RDX). miR-409-5p is predicted to target MDM2. miR-708-5p targets caspase-2 (CASP2) and is predicted to target leukemia inhibitor factor (LIF). P-values were calculated using Student t-test. *, ** and *** indicate P <0.05, 0.01 and 0.001, respectively. B. Effect of miRNA transfection on target regulation. Scramble control (miR-scramble) and miRNA mimics for miR-409-3p, miR-409-5p and miR-708-5p were transfected in either SLK or SLKK cells. Quantitative real-time polymerase chain reaction revealed the target expression for these miRNAs and the relative value is presented as the mean ± standard deviation based on 3 independent experiments. Statistical analysis and its representation are as in Fig 4A.
miRNAs predicted to target differentially expressed mRNAs using GSEA.
| miRNA | Target Sequence | Putative target genes (T) | Genes in Overlap (O) | Ratio O/T | P-value | FDR |
|---|---|---|---|---|---|---|
|
| ||||||
| miR-29c-3p | TGGTGCT | 521 | 33 | 0.0663 | 1.40x10-8 | 3.09x10-7 |
| let-7i-5p | CTACCTC | 391 | 25 | 0.0639 | 6.53x10-7 | 6.87x10-6 |
| miR-326 | CCCAGAG | 155 | 13 | 0.0839 | 1.94x10-5 | 1.07x10-4 |
| miR-503-5p | CGCTGCT | 24 | 3 | 0.125 | 1.24x10-2 | 2.75x10-2 |
|
| ||||||
| miR-203a-3p | CATTTCA | 287 | 29 | 0.1010 | 4.07x10-19 | 8.99x10-17 |
| miR-148a-3p | TGCACTG | 304 | 22 | 0.0724 | 7.03x10-12 | 1.41x10-10 |
| miR-212-3p | GACTGTT | 161 | 13 | 0.0807 | 3.91x10-8 | 2.88x10-7 |
| miR-369-3p | GTATTAT | 207 | 14 | 0.0676 | 1.09x10-7 | 7.55x10-7 |
| miR-128-3p | CACTGTG | 337 | 17 | 0.0504 | 3.38x10-7 | 2.02x10-6 |
| miR-377-3p | TGTGTGA | 200 | 13 | 0.0650 | 4.88x10-7 | 2.70x10-6 |
| miR-452-5p | GAGACTG | 94 | 9 | 0.0957 | 1.17x10-6 | 5.63x10-6 |
| miR-323a-3p | TAATGTG | 160 | 11 | 0.0688 | 2.14x10-6 | 9.85x10-6 |
| miR-380-3p | ATTACAT | 102 | 9 | 0.0882 | 2.33x10-6 | 1.05x10-5 |
| miR-381-3p | CTTGTAT | 206 | 11 | 0.0534 | 2.36x10-5 | 8.83x10-5 |
| miR-7-5p | GTCTTCC | 169 | 9 | 0.0533 | 1.31x10-4 | 4.21x10-4 |
| miR-485-3p | TGTATGA | 153 | 8 | 0.0523 | 3.49x10-4 | 9.88x10-4 |
| miR-224-5p | GTGACTT | 158 | 8 | 0.0506 | 4.32x10-4 | 1.19x10-3 |
| miR-409-3p | AACATTC | 142 | 7 | 0.0493 | 1.14x10-3 | 2.90x10-3 |
| miR-205-5p | ATGAAGG | 157 | 7 | 0.0446 | 2.03x10-3 | 4.73x10-3 |
| miR-134-5p | CAGTCAC | 52 | 4 | 0.0769 | 2.74x10-3 | 6.18x10-3 |
| miR-299-3p | CCCACAT | 54 | 4 | 0.0741 | 3.14x10-3 | 6.94x10-3 |
Using our list of differentially expressed mRNAs, we predicted which miRNAs would be upstream inhibitors with the Molecular Signatures Pathways Database (MSigDB). The overlap between the MSigDB output and our miRNA-Seq data highlighted 21 miRNAs that were differentially expressed in SLKK compared to SLK cells. Columns identify their names, the target sequence used to identify base complementarity with the input mRNA, the total number of putative target genes for a given miRNA, the number of putative targets that overlap with our input mRNA list, the percentage ratio between the overlap and the total number of putative targets, and its associated P-value and false discovery rate (FDR), correcting for multiple hypothesis testing.
Fig 5Workflow of integrated miRNA-mRNA association analysis using IPA.
This experimental workflow shows the various filters used to associate miRNA-Seq and mRNA-Seq data. Numbers are presented as Total differentially expressed miRNAs or mRNAs (Up-regulated/Down-regulated).
Ingenuity analysis predicts inversely correlated miRNAs and mRNAs pairs.
| miRNA | Log2 Fold Change | # Target gene | Name of top 5 target genes |
|---|---|---|---|
|
| |||
| miR-708-5p | 2.67 | 17 | FOXN3, RGL1, POU6F1, RNF150, PAPPA |
| miR-3614-5p | 2.16 | 2 | FOXN3, MERTK |
| miR-342-5p | 2.04 | 37 | VANGL2, NR4A1, KIF21B, GNG4, ITPRIP |
| miR-146b-5p | 1.64 | 19 | NRIP3, SDK1, ZNF90, SYT1, KCNIP3 |
| miR-877-5p | 1.56 | 2 | SUSD5, PNPO |
| miR-146b-3p | 1.46 | 12 | VANGL2, TSKU, CYFIP2, ASB6, ZNF488 |
|
| 1.23 | 81 | NAV2, C1orf21, FOXN3, GPR37, DUSP2 |
| miR-3664-3p | 1.21 | 7 | SPOCK1, PNMA2, CD6, CBX6, FAM109A |
| miR-3152-5p | 1.18 | 6 | SRSF8, CTNNA2, CSPG5, PPARGC1A, SLITRK4 |
|
| 1.17 | 20 | C1orf21, KIF5C, MOB3B, APLN, MYOM3 |
| miR-4745-5p | 1.10 | 13 | FBXL7, LONRF2, ST6GALNAC3, MOB3B, GAREM |
|
| 1.04 | 86 | C1orf21, FOXN3, TRHDE, LIN28B, PDGFB |
| miR-21-3p | 1.03 | 4 | LIN28B, SHC3, ANO5, FAM117A |
|
| |||
|
| -10.99 | 23 | SLCO2B1, FGB, CAST, RNF144B, DPP8 |
|
| -9.15 | 4 | FAM8A1, STAM2, MTMR6, PNN |
| miR-376c-3p | -7.25 | 6 | TGFBR3, FHDC1, SLC7A11, SECISBP2L, TBC1D12 |
|
| -7.11 | 1 | LPP |
| miR-409-5p | -6.45 | 4 | FAM102B, TBC1D15, MDM2, SRSF11 |
|
| -6.31 | 1 | KIAA1430 |
| miR-758-3p | -5.39 | 14 | C2CD4A, NTM, RAB27B, NUDT12, NCOA3 |
|
| -5.07 | 3 | GOLGA8A/GOLGA8B, UBA6, ZMYM4 |
|
| -4.86 | 53 | ID4, SLCO2B1, PTGFR, UNC5C, ICK |
| miR-411-5p | -4.52 | 2 | NR3C1, RYBP |
| miR-654-3p | -4.49 | 2 | GMFB, ZNF91 |
| miR-323b-3p | -4.47 | 3 | SPAST, EIF1AX, SMIM13 |
| miR-133a | -4.23 | 33 | HAPLN1, ID4, NDRG1, PLXNA2, ARRB1 |
| miR-654-5p | -4.03 | 8 | LZTS1, UNC5C, FAM8A1, PDGFRB, STK38 |
| miR-369-5p | -4.17 | 1 | ID4 |
| miR-485-5p | -3.28 | 13 | NTM, MLLT3,ZMF527, PLEKHA5, UPF2 |
|
| -2.96 | 4 | TCF4, SLC16A7, SP4, ITGAV |
|
| -2.29 | 27 | GATA3, GSE1, AXIN2, UNC5C, SECISBP2L |
| miR-3173-5p | -2.05 | 4 | ADAMTS15, STC2, PEAK1, SKP1 |
| miR-1914-5p | -1.97 | 3 | SKIDA1, GLS, PAQR8 |
|
| -1.89 | 21 | HAPLN1, BTG2, ENPP4, CTDSPL2, KDM7A |
| miR-129-5p | -1.84 | 21 | NTM, GSE1, ARRDC3, TCF4, CTDSPL2 |
| miR-2355-5p | -1.64 | 10 | CDH1, PLXNA2, LIMA1, ELF3, BTG2 |
|
| -1.61 | 45 | SPTLC3, ADAMTS15, SKIDA1, ARRDC3, SLC7A11 |
| miR-4786-5p | -1.49 | 5 | PLEKHA5, SNRNP48, TRIM59, COG6, SSR1 |
| miR-149-5p | -1.42 | 14 | ID4, CD34, SORT1, MCTP2, PAQR5 |
| miR-625-5p | -1.31 | 13 | RUNX3, PLCB2, SPN, ARRB1, AXIN2 |
| miR-450a-5p | -1.23 | 1 | DUSP10 |
| miR-548h-5p | -1.15 | 2 | EDIL3, SMAD5 |
| miR-4677-3p | -1.13 | 1 | RPS27L |
| miR-196b-5p | -1.09 | 14 | TGFBR3, DCDC2, FAM102B, PTPRG, BLOC1S6 |
|
| -1.02 | 49 | HAPLN1, TGFBR3, SLC35F3, DTX4, NEDD4 |
Using our lists of differentially expressed miRNAs and mRNAs as input for the Ingenuity Pathway Analysis (IPA), we found that 45 differentially expressed miRNAs target 480 mRNAs (medium and high confidence). Only mRNAs and miRNAs with opposite differential expression are shown in this table. Columns identify the miRNA name, its log2-transformed expression fold change between SLKK and SLK cells, the number of identified targets, and the five or less most differentially expressed targets. In bold are miRNA prediction overlapping with GSEA analysis (Table 1).
miRNA-mRNA pairs found inversely correlated and validated in the literature.
| miRNA | Known Target | Reference |
|---|---|---|
|
| ||
| let-7i-5p | ATAD3B, BCL2L1, CCND1, CDIPT, DUSP23, FAM105A, F2, GAK, GPR56, GYS1, MARS2, POLD2, POM121/POM121C, RHOB, RHOG, TAGLN | Selbach et al., 2009 (Nature) |
| miR-29c-3p | COL1A1, DUSP2, GPR37, KLF4, LOXL2, MAPRE2, MYBL2, TGFB3 | Li et al., 2009 (J Biol Chem) |
| miR-146b-5p | IRAK2, NOVA1, PTGES2, SYT1 | Hou et al. 2009 (J Immunol) |
| miR-503-5p | CCND1 | Jiang et al., 2009 (BMC Cancer) |
| miR-485-5p | MDM2 | Ratoviski et al., 2014 (Cell Cycle) |
| miR-708-5p | CASP2 | Song et al., 2013 (J Cancer Res Clin Oncol) |
|
| ||
| miR-129-5p | TNPO1 | Dyrskjot et al., 2009 (Cancer Res) |
| miR-205-5p | ZEB1 | Gregory et al., 2008 (Nat Cell Biology) |
| miR-409-3p | FGB, RDX | Fort et al. 2010 (Blood) |
This table shows the association between miRNAs and mRNAs that were significantly dysregulated in SLKK cells compared to SLK cells. Only the miRNA-mRNA pairs experimentally validated in the literature are shown here. The majority of the targets were identified through IPA-integrated TarBase v5.0 and others independently.
Fig 6Implications of miRNA-mRNA pairs in Pathogen-Influenced Signaling.
A total of 17 miRNAs and 28 mRNA targets are involved in the super pathway entitled ‘Pathogen-Influenced Signaling’. Only experimentally validated and highly predicted targets are presented here. The top part shows the up-regulated miRNAs and respective down-regulated targets. The bottom part shows the down-regulated miRNAs and respective up-regulated targets. The intensity of colors represents the extent of the up-regulation or down-regulation, in red and green respectively.
Canonical pathways affected by differentially expressed miRNA-mRNA pairs.
| Ingenuity Canonical Pathways | P-value | Ratio (% of genes in pathway) | Dysregulated target gene | Dysregulated miRNA |
|---|---|---|---|---|
| Regulation of theEpithelial-to-Mesenchymal Transition Pathway | 2.5 x 10–3 | 12/182 (6.6%) |
|
|
| IL-8 Signaling | 7.39 x 10–3 | 11/183 (6.0%) | BCL2L1, CCND1, |
|
| Clathrin-mediatedEndocytosis Signaling | 7.68 x 10–3 | 11/184 (6.0%) |
|
|
| Wnt/β-catenin Signaling | 1.02 x 10–2 | 10/166 (6.0%) |
|
|
The 480 differentially expressed genes targeted by miRNAs between SLKK and SLK cells were used as input for the Ingenuity pathway analysis (IPA). Here, we highlighted 4 of the top 10 enriched pathways that are relevant to KSHV pathogenesis. Columns identify the pathway name, its associated P-value, the ratio between dysregulated genes and genes in the pathway, which dysregulated target gene and miRNA are involved. Genes or miRNAs in bold and normal font were found up-regulated and down-regulated, respectively, by chronic KSHV infection.